Cell Therapeutics, Spectrum Form Joint Venture

11/26/08Follow @gthuang

Seattle-based Cell Therapeutics announced it has teamed up with Spectrum Pharmaceuticals of Irvine, CA, to create a 50-50 joint venture, RIT Oncology, to commercialize and develop the cancer drug Zevalin. The drug for non-Hodgkin’s lymphoma, which Xconomy has written about extensively, will be marketed in the U.S.

Gregory T. Huang is Xconomy's Deputy Editor, National IT Editor, and the Editor of Xconomy Boston. You can e-mail him at gthuang@xconomy.com. Follow @gthuang

By posting a comment, you agree to our terms and conditions.